Pharmerica (PMC) Tops Q1 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- Fed’s Warsh says central bank won’t tolerate high inflation
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
PharMerica Reports First Quarter 2015 Results
May 7, 2015 8:01 AM EDTSolid Year Over Year Improvement in Revenue, Gross Profit, Adjusted EBITDA and Adjusted Diluted Earnings Per Share
Reaffirms Annual 2015 Guidance
LOUISVILLE, Ky.--(BUSINESS WIRE)-- PharMerica Corporation (NYSE: PMC), a national provider of institutional, specialty home infusion, hospital and oncology pharmacy services, today reported its financial results for the first quarter ended March 31, 2015.
   1Q15 Results  ÂComparison to
1Q14
  Comparison to4Q14
Revenue $511.6 million Increase of 13.1% Decrease of 2.3% Adjusted EBITDA $37.4 million Increase of 25.9%... More